News | May 13, 2007

New Coalition to Seek Federal Action Against Sudden Cardiac Arrest

May 14, 2007 — More than 25 leading heart advocacy groups have joined to form the Sudden Cardiac Arrest (SCA) Coalition – the very first coalition dedicated to advancing increased research, awareness and educational efforts to address the nation’s number one cardiovascular killer. The Coalition, announced as part of Heart Rhythm 2007, the Society’s 28th Annual Scientific Sessions, will urge Congress and the federal agencies involved in national health policies and programs, to devote more resources to greater public awareness of SCA, research and access to life-saving therapies.

“Sudden Cardiac Arrest is a leading cause of death in this country, taking the lives of more than 250,000 people each year – more than breast cancer, lung cancer, stroke or AIDS,” said Dr. Dwight Reynolds, president of the Heart Rhythm Society, one of the founding members of the SCA Coalition. “It occurs abruptly and without warning, and two-thirds of SCA deaths occur without any prior indications of heart disease. But the truth is that SCA is not always a random event – yet even those of us in the medical community do not always have the tools to properly identify those at risk and prevent attacks.”

To address the public health crisis, the SCA Coalition is made up of advocates from across the spectrum — from physicians and allied health professionals, to patients and caregivers, to first responders and athletic trainers. These groups come together under the Coalition to use their collective strength as a national voice to stop sudden cardiac arrest.

Joined by SCA Coalition members and a local survivor of SCA, Dr. Reynolds spoke of the life-saving possibilities of the Coalition’s work. “As with any public health crisis, the U.S. government and its depth of medical resources offers the best hope for arming the medical community with the research and knowledge it needs, and reaching the American public to provide a level of awareness that can make a difference. The government has already made great strides in research, awareness, and treatment advances for many of our nation’s major health threats – like breast cancer, lung cancer, stroke and AIDS. But now with the passion and hard work of the SCA Coalition, we can focus the government’s attention and significant resources on a killer that takes more lives each year than any of those diseases.”

Over the next year, the SCA Coalition will encourage the introduction and passage of an Omnibus bill that, if passed, will provide the U.S. Department of Health and Human Services with the resources and the imperative to develop and implement a comprehensive education and research program for SCA. This will include appropriations for medical screening and tracking studies, as well as public awareness and education campaigns. The bill will also include a resolution to create a National Sudden Cardiac Arrest Week, to set aside time each year to focus national public attention on this deadly killer.

Related Content

Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
Overlay Init